PL3217998T3 - Kompozycje zawierające apoekworynę do stosowania w sposobie leczenia śmierci komórek neuronów z powodu niedokrwienia przez podanie doustne - Google Patents

Kompozycje zawierające apoekworynę do stosowania w sposobie leczenia śmierci komórek neuronów z powodu niedokrwienia przez podanie doustne

Info

Publication number
PL3217998T3
PL3217998T3 PL15858766T PL15858766T PL3217998T3 PL 3217998 T3 PL3217998 T3 PL 3217998T3 PL 15858766 T PL15858766 T PL 15858766T PL 15858766 T PL15858766 T PL 15858766T PL 3217998 T3 PL3217998 T3 PL 3217998T3
Authority
PL
Poland
Prior art keywords
apoaequorin
ischemia
treatment
oral administration
cell death
Prior art date
Application number
PL15858766T
Other languages
English (en)
Inventor
Mark Y. Underwood
James R. MOYER Jr.
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of PL3217998T3 publication Critical patent/PL3217998T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL15858766T 2014-11-11 2015-11-11 Kompozycje zawierające apoekworynę do stosowania w sposobie leczenia śmierci komórek neuronów z powodu niedokrwienia przez podanie doustne PL3217998T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462078099P 2014-11-11 2014-11-11
PCT/US2015/060116 WO2016077437A1 (en) 2014-11-11 2015-11-11 Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation
EP15858766.7A EP3217998B1 (en) 2014-11-11 2015-11-11 Apoaequorin-containing compositions for use in a method for the treatment of neuronal cell death from ischemia by oral administration

Publications (1)

Publication Number Publication Date
PL3217998T3 true PL3217998T3 (pl) 2022-07-11

Family

ID=55954981

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15858766T PL3217998T3 (pl) 2014-11-11 2015-11-11 Kompozycje zawierające apoekworynę do stosowania w sposobie leczenia śmierci komórek neuronów z powodu niedokrwienia przez podanie doustne

Country Status (25)

Country Link
US (1) US20180214516A1 (pl)
EP (1) EP3217998B1 (pl)
JP (1) JP6861162B2 (pl)
KR (1) KR20170072350A (pl)
CN (1) CN107106649A (pl)
AU (2) AU2015346430B2 (pl)
BR (1) BR112017009599A2 (pl)
CA (1) CA2966891C (pl)
CY (1) CY1125295T1 (pl)
DK (1) DK3217998T3 (pl)
ES (1) ES2910021T3 (pl)
HK (1) HK1243343A1 (pl)
HR (1) HRP20220749T1 (pl)
HU (1) HUE059107T2 (pl)
IL (1) IL252070B (pl)
LT (1) LT3217998T (pl)
MA (1) MA40959A (pl)
MX (1) MX2017006063A (pl)
NZ (1) NZ731340A (pl)
PL (1) PL3217998T3 (pl)
PT (1) PT3217998T (pl)
RS (1) RS63269B1 (pl)
SG (2) SG11201703690XA (pl)
SI (1) SI3217998T1 (pl)
WO (1) WO2016077437A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532936A (ja) 2016-09-23 2019-11-14 クインシー バイオサイエンス,リミティド ライアビリティ カンパニー アポエクオリンおよびビタミンd含有組成物およびそれらの使用方法
AU2021225815B2 (en) * 2020-02-24 2026-04-09 Quincy Bioscience, Llc Apoaequorin and curcumin containing compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ214563A (en) * 1984-12-31 1991-05-28 Univ Georgia Production of apoaeqorin using recombinant dna
BRPI0909435A2 (pt) * 2008-03-11 2017-06-13 Quincy Bioscience Llc composição e método para tratar de um sintoma ou distúrbio associado com o desequilíbrio do cálcio, uso da apoequorina, e, apoaequorina
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
WO2013074798A1 (en) * 2011-11-15 2013-05-23 Quincy Bioscience, Llc Apoaequorin for reducing neuronal injury due to ischemia
HUE041492T2 (hu) * 2012-09-27 2019-05-28 Quincy Bioscience Llc Szklerózis multiplex szimptómáinak enyhítésére szolgáló módszerek apoaequorin tartalmú készítményekkel

Also Published As

Publication number Publication date
CA2966891A1 (en) 2016-05-19
SI3217998T1 (sl) 2022-07-29
JP6861162B2 (ja) 2021-04-21
EP3217998A1 (en) 2017-09-20
IL252070B (en) 2022-06-01
HK1243343A1 (zh) 2018-07-13
AU2015346430A1 (en) 2017-05-25
NZ731340A (en) 2018-11-30
JP2017535607A (ja) 2017-11-30
PT3217998T (pt) 2022-04-05
US20180214516A1 (en) 2018-08-02
KR20170072350A (ko) 2017-06-26
DK3217998T3 (da) 2022-04-25
IL252070A0 (en) 2017-07-31
HUE059107T2 (hu) 2022-10-28
CN107106649A (zh) 2017-08-29
LT3217998T (lt) 2022-04-11
AU2018279057A1 (en) 2019-01-17
SG10202108723PA (en) 2021-09-29
CY1125295T1 (el) 2025-03-28
BR112017009599A2 (pt) 2017-12-19
WO2016077437A1 (en) 2016-05-19
SG11201703690XA (en) 2017-06-29
AU2015346430B2 (en) 2019-01-03
EP3217998A4 (en) 2018-06-27
HRP20220749T1 (hr) 2022-09-02
MA40959A (fr) 2017-09-19
EP3217998B1 (en) 2022-03-23
CA2966891C (en) 2023-07-04
RS63269B1 (sr) 2022-06-30
HK1244223A1 (en) 2018-08-03
MX2017006063A (es) 2017-07-27
ES2910021T3 (es) 2022-05-11

Similar Documents

Publication Publication Date Title
GB201419257D0 (en) Pharmaceutical compositions
GB201618482D0 (en) Pharmaceutical compositions
GB201409471D0 (en) Pharmaceutical composition
IL252893A0 (en) Pharmaceutical dosage form for administration to mucous membranes
DK3229816T3 (en) Proton-bindende polymerer til oral administration
IL249553A0 (en) Pharmaceutical preparations
ZA201605263B (en) Pharmaceutical composition for topical administration
GB201409488D0 (en) Pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
SG11201702700UA (en) Methods for the treatment of peri-implantitis
SI3157506T1 (sl) Oralni farmacevtski sestavek z zamaskiranim okusom
PL3166572T3 (pl) Kompozycje do higieny jamy ustnej zwalczające kamień nazębny
ZA201508726B (en) Pharmaceutical composition
ZA201502073B (en) Pharmaceutical composition
IL250817A0 (en) pharmaceutical preparations
IL259073A (en) History of abscisic acid - converted at the 3' position
HUE059107T2 (hu) Apoaequorin-tartalmú készítmények az ischaemia miatti idegsejthalál kezelési módszerében való alkalmazásra, szájon át történõ adagolással
LT3089740T (lt) Farmacinė kompozicija
SG11201608123VA (en) Pharmaceutical composition for external use
SG10201504332VA (en) Pharmaceutical Composition
GB201616880D0 (en) Compound for use in medicine
PL3191106T3 (pl) Kompozycja zawierająca mikroalgę wzbogaconą w krzem do stosowania terapeutycznego
SG11201608124XA (en) Pharmaceutical composition for external use
HUP1400518A2 (hu) Eljárás tofacitinib elõállítására
SG11201608122PA (en) Pharmaceutical composition for external use